BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24970819)

  • 1. NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.
    Giesen E; Jilaveanu LB; Parisi F; Kluger Y; Camp RL; Kluger HM
    Oncotarget; 2014 Jul; 5(14):5209-17. PubMed ID: 24970819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma.
    Demirović A; Džombeta T; Tomas D; Spajić B; Pavić I; Hudolin T; Milošević M; Cupić H; Krušlin B
    Pathol Res Pract; 2010 Oct; 206(10):695-9. PubMed ID: 20591578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
    Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
    Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
    Szender JB; Papanicolau-Sengos A; Eng KH; Miliotto AJ; Lugade AA; Gnjatic S; Matsuzaki J; Morrison CD; Odunsi K
    Gynecol Oncol; 2017 Jun; 145(3):420-425. PubMed ID: 28392127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers.
    Park TS; Groh EM; Patel K; Kerkar SP; Lee CC; Rosenberg SA
    J Immunother; 2016 Jan; 39(1):1-7. PubMed ID: 26641256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma.
    Aung PP; Liu YC; Ballester LY; Robbins PF; Rosenberg SA; Lee CC
    Hum Pathol; 2014 Feb; 45(2):259-67. PubMed ID: 24290058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
    Pollack SM; Jungbluth AA; Hoch BL; Farrar EA; Bleakley M; Schneider DJ; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
    Cancer; 2012 Sep; 118(18):4564-70. PubMed ID: 22359263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
    Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
    J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.
    Iura K; Kohashi K; Ishii T; Maekawa A; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Matsumoto Y; Iwamoto Y; Oda Y
    Virchows Arch; 2017 Sep; 471(3):383-392. PubMed ID: 28744588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma].
    Zhang WM; Xiao G; Zhang M; Guo AL; Dong Y; Wen JM
    Zhonghua Bing Li Xue Za Zhi; 2005 Apr; 34(4):202-5. PubMed ID: 16091172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue.
    Li M; Yuan YH; Han Y; Liu YX; Yan L; Wang Y; Gu J
    Clin Cancer Res; 2005 Mar; 11(5):1809-14. PubMed ID: 15756003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma].
    Zhang WM; Xiao G; Xie D; Zhang M; Guo AL; Wen JM
    Ai Zheng; 2005 May; 24(5):622-6. PubMed ID: 15890110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.
    Shurell E; Vergara-Lluri ME; Li Y; Crompton JG; Singh A; Bernthal N; Wu H; Eilber FC; Dry SM
    Oncotarget; 2016 Nov; 7(45):72860-72867. PubMed ID: 27655679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NY-ESO-1 expression in meningioma suggests a rationale for new immunotherapeutic approaches.
    Baia GS; Caballero OL; Ho JS; Zhao Q; Cohen T; Binder ZA; Salmasi V; Gallia GL; Quinones-Hinojosa A; Olivi A; Brem H; Burger P; Strausberg RL; Simpson AJ; Eberhart CG; Riggins GJ
    Cancer Immunol Res; 2013 Nov; 1(5):296-302. PubMed ID: 24777967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?
    Neumann E; Engelsberg A; Decker J; Störkel S; Jaeger E; Huber C; Seliger B
    Cancer Res; 1998 Sep; 58(18):4090-5. PubMed ID: 9751617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.
    Akcakanat A; Kanda T; Koyama Y; Watanabe M; Kimura E; Yoshida Y; Komukai S; Nakagawa S; Odani S; Fujii H; Hatakeyama K
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):95-100. PubMed ID: 15118836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NY-ESO-1 protein expression and humoral immune responses in prostate cancer.
    Fosså A; Berner A; Fosså SD; Hernes E; Gaudernack G; Smeland EB
    Prostate; 2004 Jun; 59(4):440-7. PubMed ID: 15065093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors.
    Velazquez EF; Jungbluth AA; Yancovitz M; Gnjatic S; Adams S; O'Neill D; Zavilevich K; Albukh T; Christos P; Mazumdar M; Pavlick A; Polsky D; Shapiro R; Berman R; Spira J; Busam K; Osman I; Bhardwaj N
    Cancer Immun; 2007 Jul; 7():11. PubMed ID: 17625806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.
    Ademuyiwa FO; Bshara W; Attwood K; Morrison C; Edge SB; Karpf AR; James SA; Ambrosone CB; O'Connor TL; Levine EG; Miliotto A; Ritter E; Ritter G; Gnjatic S; Odunsi K
    PLoS One; 2012; 7(6):e38783. PubMed ID: 22761704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.